Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons
Una D. Mccann, George A. Ricaurte
April 5, 1991 DOI: 10.1016/0006-8993(91)91297-e (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal experimental study |
|---|---|
| Population | Rats |
| Interventions | alpha-methyldopamine (a-MeDA) a-MeDOPA 3-O-Me-a-MeDOPA |
| Topics | Serotonin |
| Key findings | Neither of MDA's two major metabolites, a-MeDA and 3-O-Me-a-MeDA, nor their precursors produced lasting depletion of brain serotonin (5-HT) in rats. The authors suggest that neither major metabolite mediates MDA's toxic effects on 5-HT neurons, and that a minor metabolite or alternate mechanisms may be responsible. |
Abstract
The two major metabolites of (-+)3,4-methylenedioxyamphetamine (MDA), alpha-methyldopamine (a-MeDA) and 3-O-methyl-amethyldopamine (3-O-Me-a-MeDA), were administered to rats intracerebroventricularly and into brain parenchyma. In addition, their precursors, (a-MeDOPA and 3-O-Me-a-MeDOPA, respectively) were administered systemically, individually and in combination. None of these treatments produced a lasting depletion of brain serotonin (5-HT). These findings suggest that neither of MDA's major metabolites mediate its toxic effects on 5-HT neurons and that either a minor metabolite is responsible or that alternate mechanisms are involved. (+)3,4-Methylenedioxyamphetamine (MDA)is one of ular, this investigation evaluated the 5-HT neurotoxic _: several ring-substituted amphetamine derivatives [3,4- potential of alpha-methyl-dopamine (a-MeDA) and 3methylenedioxymethamphetamine (MDMA, 'Adam'), 3, O-methyl-a-methyl-dopamine (3-O-Me-a-MeDA), which
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |
Citations in the library
Cited by 14
- Human Pharmacology of MDMA Therapeutic Drug Monitoring March 19, 2004
- 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans Addiction May 1, 1994
- Glutathione and N-Acetylcysteine Conjugates of α-Methyldopamine Produce Serotonergic Neurotoxicity: Possible Role in Methylenedioxyamphetamine-Mediated Neurotoxicity Chemical Research in Toxicology November 19, 1999
- Effects of Intracerebroventricular Administration of 5-(Glutathion-S-yl)-α-methyldopamine on Brain Dopamine, Serotonin, and Norepinephrine Concentrations in Male Sprague-Dawley Rats Chemical Research in Toxicology 1996
- Synthesis and Neurotoxicity Profile of 2,4,5-Trihydroxymethamphetamine and Its 6-(N-Acetylcystein-S-yl) Conjugate Chemical Research in Toxicology May 10, 2011
and 9 more in the library
Cites 15
- Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity Journal of Neuroscience August 1, 1988
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Journal of Pharmacology and Experimental Therapeutics September 1, 1987
- Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals Science September 6, 1985
- (±3,4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates JAMA July 1, 1988
and 10 more in the library